Glenmark Pharma

1977
 
 - The Company was incorporated on 18th, November, as Glenmark
 Pharmaceuticals Private Limited under the Companies Act, 1956, and
 became a deemed Public Company on July 1, 1990, then again became a
 private Company on September 27, 1990, the word Private was deleted
 on
 July 1, 1991 and became a Public Limited Company on January 12,
 1996.
 
 - The Company is engaged in Research & Development, manufacturing
 and
 marketing of Pharmaceutical Formulations, domestically as well as
 overseas.  The Company has two brands i.e. Ascoril Expectorant and
 Candid-B among the ORG top 300 leading Pharmaceutical brands in
 India.
 
 - The Company has a manufacturing facility at Satpur, Nasik. 
 Besides
 manufacturing Oral Tablets, Liquids and Capsules it also equipped to
 manufacture Topicals - Creams, Lotions, Ointments and Powders.  The
 plant has been awarded the WHO GMP Certificate indicative of the
 fact
 that the facilities and operations fully conform to the WHO
 requirements on quality standards.
 
 1979
 
 - The company entered the anti-fungal market, where competition was
 less due to the relatively smaller market size, by introducing
 Candid
 Cream.
 
 - The Company launched Candid Lotion.  It also introduced Candid
 V-3,
 Candid V-1 and Candid V-Gel.
 
 1981 
 
 - The Company launced Candid-B Cream, a topical anti-fungal steroid
 combination to target the hitherto untapped market.
 
 1985
 
 - Candid Mouth Paint was launched for oral thrush, targeted at
 Paediatricians.  The Company launched Ascoril, a cough expectorant,
 and
 it is one of the most successful brands of the Company and is ranked
 103rd as per ORG Aug'99-MAT.
 
 1987 
 
 - The Company started a Research and Development Department at it's
 Nasik factory.
 
 1990 
 
 - The Company launched Candiderma and it is now the number two brand
 in
 its segment with a market share of 6.6%.
 
 1993 
 
 - The Company launched Candid Ear Drops.
 
 - The Company proposes to implement an ERP system, which is expected
 to
 improve operational efficiencies and assist in monitoring
 performance.
 The Company is creating a backbone for setting up the ERP system
 including purchase of requisite hardware and connectivity between
 Factories/Branches/Depots via leased lines and VSAT.
 
 - The Company proposes to implement the Sales & Distribution and
 Finance Module, followed by the Production and Material Resource
 Planning Module.
 
 1995 
 
 - The Company launched Candid TV Suspension and Candidtral.
 
 - The Company has created an Employee Welfare Trust (Trust) called
 Glenmark Pharmaceuticals Limited Employee Welfare Trust to implement
 the Employee Stock Option Plan.
 
 1997 
 
 - The Company established a Cardiac Center at Dadar, in Mumbai.
 
 - Glenmark proposes to set up a drug discovery center in the Thane
 Belapur area (suburb of Mumbai).
 
 1999
 
 - The Company proposes to launch line extensions and new products to
 expand its product basket in the existing segments and also
 capitalise
 on its doctor penetration.  The Company also proposes to establish a
 subsidiary in Canada, to penetrate the market.
 
 - The Company allotted 1,75,000 warrants to the Trust for cash on
 September 20th, at Rs 1.0 per warrant.
 
 - Altacef, Suprocin, Suprocin B, Scalpe and Elovera were launched
 during the year and has been the most successful product by the
 Company, recording high growth.
 
 - The company is coming out with a public issue of 26,70,000 equity
 shares of Rs. 10 each for cash at a premium of Rs. 190 per share to
 fund its proposed expansion plan.  The issue will open for
 subscription
 on December 10.
 
 - The company is setting up a soft gel capsule manufacturing
 facility
 at Goa at a total cost of Rs 19.4 crore for exports to US and a
 research and development centre in Mumbai at a cost of over Rs 11
 crore.
 
 - Glenmark Pharmaceuticals, a Mumbai-based company, will be the
 first
 to test the waters from Industrial sector, viz., pharmaceuticals
 sector, while many other companies are waiting in the wing.
 
 2000 
 
 - The Glenmark Pharmaceutical scrip opened its innings on the Bombay
 Stock Exchange at Rs 550, a whopping 175 per cent increase over the
 issue price of Rs 200 (including a premium of Rs 190) per share.
 
 - The Company has entered into a strategic alliance with Haller
 Group
 (HG) of Brazil.
 
 - The Company is to issue 30,00,000 No. of equity shares of Rs 10
 each
 on private placement to finance the R&D and US FDA projects as also
 several opportunities for acquisitions and alliances to achieve
 higher
 growth.
 
 - The Company is to increase the borrowing powers from Rs 25 crores
 to
 Rs 150 crores.
 
 - The Company has acquired three brands, viz. Alex, Flucort and
 Sensur
 from Lyka Labs Ltd.
 
 2001 
 
 - The board proposes to issue, through private placement, 40,00,000
 redeemable cumulative non-convertible preference shares of Rs 100
 each
 bearing dividend of not less than 9 per cent per annum and not
 exceeding 10.50 per cent per annum.
 
 2002
 
 -Establishes 'Proof of concept' in animal for their anti-diabetic /
 anti -obesity agent GRC-1087 which is a highly potent and selective
 human beta 3 andrnoceptor agoinst.
 
 -Company co-opted 3 directors Mr. Rajiv V Desai, Mr A S Mohanty, and
 Mr Sameer Paigankar in its board.
 
 -Dr Robin Pinto resigns as the director on the board of the company.
 
 -CDC Financial Services Ltd acquires 25,00,000 convertible debentures
 of the company of Rs.100 each.
 
 2003
 
 -Members approve for the disinvestment of company's right, title and
 interest in Assets & immovable property relating to manufacturing
 facilities located in at Verna, Goa.
 
 -Forays into the US generic markets and has roped in a former
 vice-president of Dr. Reddy's Laboratories to run the activities.
 
 -Declares interim dividend of 65% on the paid up equity capital of
 the company.
 
 -Directors allot 21000 equity shares to employees on ESOP scheme of
 the company.
 
 -Enters into a marketing arrangement with Philadaphia based Lannett
 Company, US to market
 the ANDA's .
 
 -Board approves for the sub division of equity shares from Rs.10 to
 Rs.2 per share.
 
 -Submitts Initial Drug Master File on Amiodarone
 
 -Fire breaks out at Kurkum factory and manufacturing operations have
 been suspended.
 
 -The  Company ties up with Apotex, Canada, for the supply of a new
 generation bulk drug in cardiac segment.
 
 -Board approves Conversion of Debentures into equity shares at a
 price of Rs 305.42 per share, resulting in allotment of 818557 equity
 shares .
 
 2004
 
 -Glenmark Pharmaceuticals Inc, USA signs Development & Marketing
 Agreement with KV Pharmaceutical Company.
 
 -Glenmark Pharmaceuticals has acquired Laboratories Klinger in Brazil
 for .2m through its wholly owned subsidiary in Brazil, Glenmark
 Farmaceuitca
 
 -Glenmark Pharmaceuticals Ltd acquires two FDA approved products from
 Clonmel Healthcare Ltd
 
 -Glenmark Pharmaceuticals SA (Switzerland), a wholly owned subsidiary
 of Glenmark Pharmaceuticals India (GPL), has entered into a
 collaboration agreement with Forest Laboratories Inc, USA, for the
 development and commercialisation of PDE4 (phosphodiesterase 4)
 inhibitor GRC 3886 for chronic obstructive pulmonary disorder (COPD)
 and asthma
 
 2005
 
 -Glenmark forges alliance with 2 US firms to sell products in US
 
 -Glenmark Pharmaceuticals & Teijin Pharma announces Collaboration
 Agreement on PDE4 inhibitor GRC 3886
 
 -Glenmark Pharmaceuticals Ltd has announced that Glenmark
 Pharmaceuticals SA (GPSA), a wholly owned Swiss subsidiary of the
 Company, acquired an Argentine marketing company Servycal S A
 (Servycal) for an undisclosed consideration
 
 -Glenmark Pharmaceuticals signs development & marketing agreement
 with InvaGen
 
 2006
 
 -Glenmark Pharmaceuticals - Glenmark USA acquires exclusive marketing
 rights to 3 additional generic products
 
 2007
 
 - Glenmark Pharmaceuticals received tentative US FDA approval for its
 ANDA for Topiramte Tablet
 
 - Glenmark receives MHRA, UK approval for its state-of-the art
 semi-solids manufacturing plant at Baddi